Actively Recruiting
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Led by Pfizer · Updated on 2026-04-07
119
Participants Needed
3
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
CONDITIONS
Official Title
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Part 1: Adults 18 to 55 years old at consent
- Part 2: Adults 18 to 70 years old at screening
- Part 1: Healthy adults determined by medical evaluation including history, physical exam, vital signs, ECG, and lab tests
- Body mass index between 17.5 and 40 kg/m2 and body weight over 50 kg
- Part 2: Clinical diagnosis of chronic atopic dermatitis for at least 1 year confirmed by photos and diagnostic criteria
- Part 2: Inadequate response to standard AD treatments (excluding systemic immunosuppressants) for at least 4 consecutive weeks within 6 to 12 months before the first dose, or documented reason topical treatments are inappropriate
- Part 2: Moderate to severe AD with affected body surface area ≥10%, Investigator Global Assessment ≥3, and Eczema Area and Severity Index ≥12 at screening and baseline
- Part 2: Otherwise healthy based on medical evaluation except for AD symptoms
- Controlled mild or moderate asthma allowed if not requiring high dose inhaled corticosteroids, systemic corticosteroids, or biologic asthma treatments
You will not qualify if you...
- History of systemic infection requiring hospitalization and intravenous antimicrobial therapy, lymphoproliferative disorders, or malignancies
- Clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or immunological/rheumatological disorders
- Significant trauma or major surgery within 1 month before first dose
- Active, latent, or inadequately treated tuberculosis infection
- Part 2: Active inflammatory skin diseases other than AD
- Part 2: Skin conditions interfering with AD evaluation or treatment response
- Part 2: Active skin infections requiring systemic treatment within 2 weeks or superficial infections within 1 week before first dose
- Part 2: Fitzpatrick Skin Type Assessment score of 5 or higher
- History of anaphylaxis except for single, avoidable allergens if participant is aware and can manage reactions
- Use of investigational or experimental therapy for AD or related inflammatory diseases within the previous year without approval
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801
Actively Recruiting
2
Miami Dermatology and Laser Research
Miami, Florida, United States, 33133
Not Yet Recruiting
3
Paddington Testing Company
Philadelphia, Pennsylvania, United States, 19103
Not Yet Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here